+44 (0) 20 3311 7700
Search our consultants’ directory
To book an appointment please call +44 (0)20 3311 7700 or email imperial.private.healthcare@nhs.net
Biography
Mr Peterson studied at University College Hospital Medical School, then undertook his neurosurgery training in London. He was appointed a consultant in 1996.
Professional qualifications: MB BS
Dr David Pinato
Director of Developmental Therapeutics, Consultant and Clinical Senior Lecturer in Medical Oncology ‘7062967Biography
Dr David J. Pinato is a Clinician Scientist and Consultant Medical Oncologist supported by the Wellcome Trust Strategic Fund (IPPRF scheme) working within the Department of Surgery and Cancer at Imperial College, London.
David leads a translational research program focusing on the early clinical implementation of novel experimental anticancer therapies to the clinic, with particular emphasis on anti-cancer immunotherapy. He has led the inception of a portfolio of first-in-class studies of immune checkpoint inhibitors in liver cancer, which has represented David’s focus of research since graduation with highest honours at the University of Piemonte Orientale “A. Avogadro” in Novara, Italy.
David completed his research training being awarded a Masters of Research in Translational Medicine and a Ph.D. in Clinical and Experimental Medicine. Whilst at Imperial as a research fellow and Ph.D. student he developed considerable experience in translational oncology within the specific setting of early phase clinical trials. As part of his ongoing collaboration with the academic pathology unit at Imperial, David devoted his research interests to the immune-phenotyping of malignancy.
Since his graduation, David matured his clinical skills attending several academic institutions in Europe including the University Hospital in Zürich, the Medical University in Vienna and the University of Ioannina in Greece. He completed his core medical training across some of the busiest acute hospitals in London, being elected member of the Royal College of Physicians (MRCP) in 2014. He has trained in Medical Oncology as part of the Royal Marsden Hospital rotation, having migrated to Imperial College in April 2015 to take up a Clinical Lectureship funded by the National Institute for Health Research (NIHR).
In 2018 David was awarded a Clinician Scientist fellowship funded by the Wellcome Trust Strategic Fund centered on the development of immunotherapy in liver cancer. Hepatocellular Carcinoma (HCC) is the most frequently occurring primary liver tumour that currently ranks 5th by incidence and 3rd by mortality on a global scale. David’s studies, supported by international collaborations, have led to the qualification of novel prognostic and predictive biomarkers in HCC, which have been published in leading journals in the field including the Journal of Clinical Oncology, Annals of Oncology, Hepatology and many others.
David’s research efforts on biomarker discovery have been recognized with the prestigious Merit Award from the American Society of Clinical Oncology (ASCO) three times in 2016, 2017, 2019 as well as a fourth Merit Award jointly awarded by ASCO and by the Society for Immunotherapy of Cancer (SITC) in 2019. In 2019 David was awarded the prestigious ASCO Global Oncology Young Investigator Award in recognition of his research on HIV-associated hepatocellular cancer. David was also awarded a prize by the British Society of Pharmacology in 2018 and the Sylvia Lawler Prize in Oncology from the Royal Society of Medicine in 2016.
David lectures internationally in the field of molecular oncology with a specific interest in HCC and acts as a reviewer for a number of peer-reviewed journals including Hepatology, Journal of Hepatology, Oncogene, OncoImmunology, Gut and many others. He has acted as peer reviewer for a number of grant awarding bodies including the MRC, Breast Cancer Now and Cancer Research UK.
He has been awarded the European School of Oncology fellowship in 2008 and the Fulbright Visiting Research Scholar Fellowship for 2010/2011.
Biography
Dr Danielle Power is a consultant clinical oncologist (cancer specialist) and radiotherapy lead clinician. Her specialist tumour sites are lung and other thoracic tumours, upper gastrointestinal cancers and thyroid cancer. Her interests include technical radiotherapy, education, patient safety and clinical outcomes.
Languages spoken: German
Biography
Mr George Reese completed his MD thesis at Imperial College, London and progressed on to a surgical training rotation around central London teaching hospitals. He undertook the pan London fellowship in colorectal surgery before being appointed as an NHS consultant at Imperial College Healthcare NHS Trust. Mr Reese has a research interest in colonic imaging.
Biography
Dr Justin Roe is a consultant clinical-academic and service lead, specialising in swallowing and communication difficulties caused by head and neck cancer, airway disorders and other complex ENT conditions. He received his first degree, majoring in psychology, in 1993 and qualified as a speech and language therapist (SLT) in 1999 from City University, London. He was awarded his MSc in swallowing research with distinction from Newcastle University in 2015 and his PhD from the Institute of Cancer Research in 2013.
He has practised at a number of London teaching hospitals. He joined the team at the National Centre for Airway Reconstruction at Imperial College Healthcare NHS Trust (ICHT) in 2016 where he is the clinical lead speech and language therapist (SLT) for the Airways/ Complex Laryngology service. He also works at the Royal Marsden NHS Foundation Trust (RMH) where he is a Consultant and the Joint Head of SLT. He holds an honorary academic appointment within the Department of Surgery and Cancer at Imperial College London. Dr Roe is involved in a number of national and international working parties and is a Royal College of Speech and Language Therapists (RCSLT) specialist clinical advisor.
To inform his clinical practice, Dr Roe has spent time at international centres of excellence, including the Netherlands Cancer Institute, Massachusetts General Hospital, Boston Medical Center and Mount Sinai Beth Israel in New York. Alongside his clinical commitments, Dr Roe’s academic work is focused on head and neck oncology, lung cancer and airway stenosis. He is a co-investigator and co-applicant on a number of clinical trials including international cooperative studies. He is also involved in qualitative research studies and is working in partnership with patients and quality improvement specialists to enhance and co-design care pathways.
Dr Roe has published extensively, including peer-reviewed scientific papers and book chapters on head and neck cancer, lung cancer, palliative care, airway stenosis and ethics. He has presented at scientific meetings and conferences internationally.
He is a member of the British Association of Head and Neck Oncologists (BAHNO), British Laryngological Association, the Dysphagia Research Society and United Kingdom Swallowing Research Group (UKSRG). He also serves on the scientific committee for the UKSRG and is a BAHNO Council Member. In 2018, he was awarded a prestigious RCSLT Fellowship for his outstanding contribution to the profession.
Biography
Dr Waqar Saleem is a consultant clinical oncologist. He trained on the north west London training scheme, qualifying for FRCR. He obtained a masters in oncology from the Institute of Cancer Research.
Dr Saleem treats tumours originating in the brain, spinal cord, prostate, bladder and skin. He has a special interest in the management of brain secondaries and is qualified to deliver stereotactic radiosurgery and radiotherapy for these tumours. Dr Saleem also delivers post-operative radiotherapy for keloid scars.
He is an enthusiastic teacher and one of the oncology unit training leads.
Research
Extreme hypofractionated external beam radiotherapy for prostate cancer – comparison of cyberknife & VMAT (MSc dissertation)
Identifying palliative radiotherapy in a national radiotherapy dataset – a single centre pilot study: poster presentation at Sharing the Vision for World-class Radiotherapy, Manchester, March 2017
Classification using real-world Radiotherapy Dataset – multi-institution project; submitted to Knowledge Discovery in Databases (KDD) conference February 2018
Prevalence of vasomotor and psychological symptoms in prostate cancer patients receiving hormonal therapy – results from a single institution experience: poster presentation at ASCO 2014 Genitourinary Cancers Symposium. JCO Abstract 2014:283 Vol 32 No 4 February Supplement
IMRT-SIB for treating the prostate and pelvic nodes in high risk localised and locally advanced prostate cancer: experience of first 100 patients: poster presentation at NCRI – Nov. 2014
Glynne-Jones R, Saleem W, Harrison M, Mawdsley S, Hall M. Background and current treatment of squamous cell carcinoma of the anus. Oncol Ther. 2016;4(2):135-72
Additional languages spoken: Hindi, Punjabi, Urdu
Biography
Professor Michael Seckl completed undergraduate training at the University of London and University of London Hospital (UCL/UCLH) obtaining a BSc in immunology in 1983 and an MBBS in 1986.
He subsequently trained in medicine and medical oncology and undertook a PhD in biochemistry and cancer biology, becoming a senior lecturer and honorary consultant in 1995.
He was promoted to reader in 2000 and professor in molecular oncology in 2002. Professor Seckl became director of the national Gestational Trophoblastic Disease Service in 2004 and established a new national service for malignant ovarian germ cell tumours in 2013. He also runs the germ cell tumour service.
Biography
Dr Rohini Sharma is a senior lecturer at Imperial College, London and is dual accredited in clinical pharmacology and medical oncology. She is also a consultant medical oncologist based at the Hammersmith Hospital campus of Imperial College Healthcare NHS Trust.
Her clinical and research interests are in hepatocellular cancer (HCC), neuroendocrine tumours (NETs) and PET imaging. Dr Sharma is the oncology lead for the specialist hepato-oncology clinic, a unique service where patients are jointly managed by a hepatologist and medical oncologist with a view to improving clinical outcomes and promoting research. She is also the oncology lead for the management of NETs.
Dr Sharma completed her medical training at the University of Adelaide, Australia and undertook her specialist oncology training at the Royal Prince Alfred Hospital, Sydney and her clinical pharmacology training at Westmead Hospital, Sydney. She was awarded an NHMRC fellowship to complete her PhD at the Westmead Millennium Institute, University of Sydney, Australia.
She was awarded the prestigious Higher Education Funding Council for England clinical senior lecturer position in May 2010.
Additional languages spoken: Hindi
